SELLAS Life Sciences Group, Inc. — Director's Dealing 2014

Jan 23, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2013-12-31

Reporting Person: Dunlap Ryan (Principal Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-12-31	Common Stock	J	2728	$1.8785	Acquired	5343	Direct

Footnotes

F1: Pursuant to the Issuer's Employee Stock Purchase Plan.